Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Interest of Branched Chain Amino Acids Associated With a Respiratory Rehabilitation Program in Patients Broncho Chronic Obstructive Pulmonary Disease (REHABAAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03644836
Recruitment Status : Completed
First Posted : August 23, 2018
Last Update Posted : February 20, 2019
Information provided by (Responsible Party):
Poitiers University Hospital

Brief Summary:
Respiratory rehabilitation is one of the main treatments for COPD in the early stages of the disease (Stage 2 of GOLD) with a recognized effect on improving the capacity of the patients to exert effort by fighting against deconditioning. the effort. This treatment also improves the quality of life of patients and reduces the risk of respiratory exacerbations. The patients are very often malnourished and various studies have proposed the addition of oral supplementation such as hormone therapy (testosterone) to improve the exercise performance of these atrophied muscles. The use of branched-chain amino acids (AARs) such as valine, leucine, isoleucine in this indication can be fully justified because they stimulate protein synthesis and promote muscle maintenance and repair.

Condition or disease Intervention/treatment Phase
Broncho Chronic Obstructive Pulmonary Disease Drug: Amino Acids Drug: Placebos Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Interest of Branched Chain Amino Acids Associated With a Respiratory Rehabilitation Program in Patients Broncho Chronic Obstructive Pulmonary Disease. Randomized Study Against Placebo
Actual Study Start Date : January 21, 2015
Actual Primary Completion Date : January 31, 2018
Actual Study Completion Date : March 5, 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Retraining with respiratory effort+ amino acids Drug: Amino Acids
Sweet taste cocoa flavored drink

Placebo Comparator: Retraining with respiratory effort+ placebo Drug: Placebos
Sweet taste cocoa flavored drink

Primary Outcome Measures :
  1. maximum oxygene uptake [ Time Frame: after 6 weeks of treatment ]
    maximum oxygene uptake measured during intensive exercise

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients Broncho Chronic Obstructive Pulmonary Disease in stages 2 and 3 of the GOLD classification, whose Maximum Expiratory Volume on the first second is between 30% and 80% of the expected theoretical value, associated with a maximal expiratory volume ratio on the first Second / Vital Capacity less than or equal to 70% of the expected theoretical value.
  • Patients of both sexes, aged 40 to 80 years
  • In case of active smoking, patients must commit to interrupting it during the respiratory rehabilitation program that will be proposed to them in this study

Exclusion Criteria:

  • - Age <40 years or> 80 years
  • Patients with a contraindication to exercise,
  • Phenylketonuria
  • Patients treated with long-term oxygen therapy and / or home ventilation will not be included.
  • Patients with acute respiratory decompensation in the three months prior to inclusion.
  • Patients with known allergy to milk, gluten, soy, egg and nuts
  • Patients taking part in another clinical trial or who have participated in a clinical trial in the 3 months preceding this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03644836

Layout table for location information
Chu de Poitiers
Poitiers, France, 86021
Sponsors and Collaborators
Poitiers University Hospital
Layout table for investigator information
Principal Investigator: Jean-Claude MEURICE Poitiers University Hospital

Layout table for additonal information
Responsible Party: Poitiers University Hospital Identifier: NCT03644836    
Other Study ID Numbers: REHABAAR
First Posted: August 23, 2018    Key Record Dates
Last Update Posted: February 20, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases